1 completed, 1 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Orygen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Staged Treatment in Early Psychosis Study Support and Problem Solving Therapy, Cognitive Behavioural Case Management, Fluoxetine - Psychotic Disorders, Personality Disorders | Phase 3 | Completed | Orygen | 342 | 2016-04-01 | 2025-10-02 |
| Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome. omega-3 PUFAs, Standard care, placebo - 22q11 Deletion Syndrome | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 80 | 2014-06-01 | 2014-02-25 |
Psychotic Disorders (2) · 22q11 Deletion Syndrome (1) · Personality Disorders (1)
Fish Oils (1) · Fluoxetine (1) · Palliative Care (1) · Standard of Care (1)
Australia (1) · Holy See (1)
Marco Armando, MD, PhD (1) · Patrick McGorry, MD, PhD (1)
U01MH105258 (1)